跳到正文
原文
MedPage Today·· 2026-10-21AI 评分41

内分泌新闻速览:约1/4美军现役男性睾酮偏低;semaglutide联合cagrilintide III期事后分析显示女性减重25%;retatrutide副作用见于Reddit讨论

1 in 4 Army Men Have Low T; GLP-1 in Menopause; Retatrutide Side Effects on Reddit

AI 导读

《JAMA》数据显示,约四分之一美国现役男性单次晨间睾酮浓度低于300 ng/dL这一低睾酮常用界值。Novo Nordisk称其semaglutide联合cagrilintide的III期试验事后分析中,绝经前、围绝经期和绝经后女性平均减重约25%。对Reddit用户使用未经批准的减重药retatrutide的分析显示,最常见不良事件词包括食欲增加、疲劳、失眠和心率升高。

正文

— News and commentary from the endocrinology world

October 20, 2026 • 2 min read

Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL, a commonly used cutoff for low testosterone. (JAMA)

Nearly half of American women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of that group were taking prescription medications for those symptoms, a CDC report found.

One in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptoms, according to findings from the National Health Interview Survey. (Annals of Internal Medicine)

Greater weight reduction from GLP-1 receptor agonists and emerging multi-hormone receptor modulators was strongly linked to larger drops in blood pressure, a meta-analysis of phase III trial data showed. (eClinicalMedicine)

Meanwhile, early research suggested GLP-1 agonists may have anti-aging potential. (CNN)

Novo Nordisk said its investigational weight-loss combination of semaglutide plus cagrilintide was associated with an average 25% weight loss among women in post-hoc analyses of a phase III trial, with similar results across pre-, peri-, and postmenopausal stages.

Walmart plans to cover over 250 prescription drugs -- including some insulins and GLP-1 drugs for diabetes -- at no cost for its employees in 2027. (CNBC)

In an analysis of Reddit users reporting use of the unapproved weight-loss drug retatrutide, the most commonly cited adverse event terms included appetite increases, fatigue, increased energy, insomnia, increases in heart rate, and muscle-related symptoms. (JAMA Network Open)

Verdiva Bio canned a phase II study evaluating a once-weekly oral GLP-1 drug candidate, citing "market evolution." (FierceBiotech)

Zealand Pharma and Generate Biomedicines announced a collaboration to use artificial intelligence in developing novel protein-based therapies for obesity and metabolic diseases.

来源:MedPage Today · medpagetoday.com